Literature DB >> 21605007

Airway purinergic responses in healthy, atopic nonasthmatic, and atopic asthmatic subjects exposed to ozone.

Charles R Esther1, David B Peden, Neil E Alexis, Michelle L Hernandez.   

Abstract

CONTEXT: Ozone exposure triggers airway inflammatory responses that may be influenced by biologically active purine metabolites.
OBJECTIVE: To examine the relationships between airway purine metabolites and established inflammatory markers of ozone exposure, and to determine if these relationships are altered in individuals with atopy or asthma.
MATERIALS AND METHODS: Mass spectrometry was utilized to measure concentrations of purine metabolites (adenosine monophosphate [AMP], adenosine, hypoxanthine, uric acid) and non-purine metabolites (taurine, urea, phenylalanine, tyrosine) in induced sputum obtained from 31 subjects with normal lung function (13 healthy controls, eight atopic nonasthmatics, and 10 atopic asthmatic [AA]) before and 4 h after ozone exposure.
RESULTS: At baseline, the purines AMP and hypoxanthine correlated with multiple inflammatory markers including neutrophil counts and the cytokines interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-α), and IL-1β (r ranged from 0.41 to 0.66, all P < 0.05). Following ozone exposure, these purines remained correlated with IL-6, IL-8, and TNF-α (r = 0.37-0.68). However, AMP and hypoxanthine increased significantly post ozone exposure in atopic nonasthmatics but not in AA. In contrast, the non-purine metabolite taurine correlated with baseline neutrophil counts (r = 0.56) and IL-6 (r = 0.53) and was elevated post-exposure in both atopic cohorts. DISCUSSION AND
CONCLUSIONS: The purine metabolites AMP and hypoxanthine are correlated with multiple inflammatory markers at baseline and after ozone exposure. However, changes in these purine metabolites after ozone appear to differ from other inflammatory markers, with less response in AA relative to atopic nonasthmatics. Purine metabolites may play a role in the signaling responses to ozone, but these responses may be altered in subjects with asthma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605007      PMCID: PMC3175355          DOI: 10.3109/08958378.2011.572096

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  35 in total

1.  Lung epithelial cells release ATP during ozone exposure: signaling for cell survival.

Authors:  Shama Ahmad; Aftab Ahmad; Glen McConville; Barbara K Schneider; Corrie B Allen; Rizwan Manzer; Robert J Mason; Carl W White
Journal:  Free Radic Biol Med       Date:  2005-03-28       Impact factor: 7.376

Review 2.  Pathophysiology and therapeutic potential of purinergic signaling.

Authors:  Geoffrey Burnstock
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

Review 3.  Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.

Authors:  M J L Bours; E L R Swennen; F Di Virgilio; B N Cronstein; P C Dagnelie
Journal:  Pharmacol Ther       Date:  2006-06-19       Impact factor: 12.310

Review 4.  Nucleotide metabolism and cell-cell interactions.

Authors:  Holger K Eltzschig; Thomas Weissmüller; Alice Mager; Tobias Eckle
Journal:  Methods Mol Biol       Date:  2006

5.  Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality.

Authors:  G J Quinlan; N J Lamb; R Tilley; T W Evans; J M Gutteridge
Journal:  Am J Respir Crit Care Med       Date:  1997-02       Impact factor: 21.405

6.  Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone.

Authors:  Michelle L Hernandez; John C Lay; Bradford Harris; Charles R Esther; W June Brickey; Philip A Bromberg; David Diaz-Sanchez; Robert B Devlin; Steven R Kleeberger; Neil E Alexis; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2010-09       Impact factor: 10.793

7.  Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction.

Authors:  Z Csoma; E Huszár; E Vizi; G Vass; Z Szabó; I Herjavecz; M Kollai; I Horváth
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

Review 8.  Adenosine signaling in asthma and chronic obstructive pulmonary disease.

Authors:  Amir Mohsenin; Michael R Blackburn
Journal:  Curr Opin Pulm Med       Date:  2006-01       Impact factor: 3.155

9.  Purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

10.  Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation.

Authors:  P F Lennon; C T Taylor; G L Stahl; S P Colgan
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

View more
  4 in total

1.  Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis.

Authors:  Charles R Esther; Raymond D Coakley; Ashley G Henderson; Yi-Hui Zhou; Fred A Wright; Richard C Boucher
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

2.  Airway drug pharmacokinetics via analysis of exhaled breath condensate.

Authors:  Charles R Esther; Richard C Boucher; M Ross Johnson; John H Ansede; Karl H Donn; Thomas G O'Riordan; Andrew J Ghio; Andrew J Hirsh
Journal:  Pulm Pharmacol Ther       Date:  2013-08-07       Impact factor: 3.410

3.  SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration.

Authors:  Megan J Webster; Boris Reidel; Chong D Tan; Arunava Ghosh; Neil E Alexis; Scott H Donaldson; Mehmet Kesimer; Carla M P Ribeiro; Robert Tarran
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

4.  SPLUNC1: a novel marker of cystic fibrosis exacerbations.

Authors:  Sara Khanal; Megan Webster; Naiqian Niu; Jana Zielonka; Myra Nunez; Geoffrey Chupp; Martin D Slade; Lauren Cohn; Maor Sauler; Jose L Gomez; Robert Tarran; Lokesh Sharma; Charles S Dela Cruz; Marie Egan; Theresa Laguna; Clemente J Britto
Journal:  Eur Respir J       Date:  2021-11-11       Impact factor: 33.795

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.